Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Tea Pemovska, PhD, Johannes Bigenzahn, MD PhD, Ismet Srndic, MSc, Alexander Lercher, MSc, Andreas Bergthaler, PhD, Adrian Cesar Razquin, PhD, Felix Kartnig, MD, Philipp B. Staber, MD PhD, Giulio Superti Furga, PhD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134769

Published: 2020

Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134440

Published: 2020

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-140776

Published: 2020

Journal Articles

Identification of Critical Phosporylation Sites within NPM-ALK That Regulate JUNB mRNA Translation.

Claudia Fuchs, Paul Vesely, Ms, Isabella Bambach, Silvia Schauer, Werner Linkesch, MD, David W. Sternberg, MD, PhD, Gerald Hoefler, MD, Philipp B. Staber, MD

Blood (2007) 110 (11): 3571.

https://doi.org/10.1182/blood.V110.11.3571.3571

Published: 2007

Journal Articles

Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.

Stefan Langner, MD, Philipp B. Staber, MD, Armin Zebisch, MD, Wilma Zinke-Cerwenka, MD, Heinz Sill, MD, Werner Linkesch, MD, Hildegard Greinix, MD, Peter Kalhs, MD, Werner Rabitsch, MD, Peter Neumeister, MD

Blood (2006) 108 (11): 5251.

https://doi.org/10.1182/blood.V108.11.5251.5251

Published: 2006

Journal Articles

NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.

Paul Vesely, MS, Philipp B. Staber, MD, Rene Ott, PhD, Montserrat Pinent, PhD, Werner Linkesch, MD, Silvia Schauer, Andelko Hrzenjak, PhD, Marshall E. Kadin, MD, David W. Sternberg, MD PhD, Gerald Hoefler, MD

Blood (2006) 108 (11): 1448.

https://doi.org/10.1182/blood.V108.11.1448.1448

Published: 2006

Journal Articles

NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.

Philipp B. Staber, MD, Paul Vesely, MS, Rene Ott, PhD, Naznin Haq, Werner Linkesch, MD, Silvia Schauer, Andelko Hrzenjak, PhD, Lukas Kenner, MD, Wilhelm Dirks, PhD, Marshall E. Kadin, MD, David W. Sternberg, MD PhD, Gerald Hoefler, MD

Blood (2006) 108 (11): 1428.

https://doi.org/10.1182/blood.V108.11.1428.1428

Published: 2006

Journal Articles

Genes Regulated by NPM-ALK Fusion Kinase Play a Key Role in the Activation of AP-1 Transcription Factors.

Philipp B. Staber, MD, Werner Linkesch, MD, Silvia Schauer, Gerit Moser, Marshall E. Kadin, MD, Willi Dirks, PhD, Gerald Hoefler, MD

Blood (2004) 104 (11): 245.

https://doi.org/10.1182/blood.V104.11.245.245

Published: 2004

Journal Articles

Two Novel Activating Germline Mutations of the C-RAF Proto-Oncogene Predisposing to Solid Tumors and Therapy-Related Acute Myeloid Leukemia.

Armin Zebisch, MD, Philipp B. Staber, MD, Katja Fischereder, Claudia Bodner, Karin Hiden, Werner Linkesch, MD, Holger W. Auner, MD, Werner Emberger, MD, Christian Windpassinger, PhD, Michael G. Schimek, PhD, Gerald Hoefler, MD, Jakob Troppmair, PhD, Heinz Sill, MD

Blood (2004) 104 (11): 3370.

https://doi.org/10.1182/blood.V104.11.3370.3370

Published: 2004

NARROW

Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Identification of Critical Phosporylation Sites within NPM-ALK That Regulate JUNB mRNA Translation.

Adding Palifermin in Allogeneic and Autologous Stem Cell Transplantation Resulted in Reduced Oral Mucositis and Enhanced Intestinal Mucosal Recovery Measured by Citrulline Serum Levels.

NPM-ALK Converts JUNB from a Tumor Suppressor to an Oncogene.

NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1.

Genes Regulated by NPM-ALK Fusion Kinase Play a Key Role in the Activation of AP-1 Transcription Factors.

Two Novel Activating Germline Mutations of the C-RAF Proto-Oncogene Predisposing to Solid Tumors and Therapy-Related Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only